tert-butyl N-[3-[3-bromo-5-[3-[(2-methylpropan-2-yl)oxycarbonylamino]propoxy]phenoxy]propyl]carbamate | 1382469-16-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: tert-butyl N-[3-[3-bromo-5-[3-[(2-methylpropan-2-yl)oxycarbonylamino]propoxy]phenoxy]propyl]carbamate
• CAS: 1382469-16-0
• 化学式: C₂₂H₃₅BrN₂O₆
• 分子量: 503.434
• InChiKey: ACACKWFHXFFMRN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  31
• 可旋转键数：
  14
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  95.1
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  tert-butyl N-[3-[3-bromo-5-[3-[(2-methylpropan-2-yl)oxycarbonylamino]propoxy]phenoxy]propyl]carbamate 在 potassium phosphate 、 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 potassium acetate 作用下， 以 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 23.0h， 生成
  参考文献：
  名称：

  Role of Amphiphilicity in the Design of Synthetic Mimics of Antimicrobial Peptides with Gram-Negative Activity

  摘要：

  Two new series of aryl SMAMPs (synthetic mimics of antimicrobial peptides) with facially amphiphilic (FA) and disrupted amphiphilic (DA) topologies were designed and synthesized to directly assess the role of amphiphilicity on their antimicrobial activity against Gram-positive and Gram-negative bacteria in closely related structures. The FA SMAMPs displayed broad spectrum antimicrobial activity against both Gram-positive S. aureus and Gram-negative E. coli, whereas the DA SMAMPs, which contained a polar amide bond in between the hydrophobic moieties, only exhibited activity toward S. aureus with increasing hydrophobicity. The integy moment (IW) was used to quantify the amphiphilicity of the SMAMPs and confirmed that it is critical for the design of SMAMPs with Gram-negative activity.

  DOI：

  10.1021/ml300307b
• 作为产物：
  描述：

  1-溴-3,5-二甲氧基苯 在 三溴化硼 、 potassium carbonate 作用下， 以 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 0.33h， 生成 tert-butyl N-[3-[3-bromo-5-[3-[(2-methylpropan-2-yl)oxycarbonylamino]propoxy]phenoxy]propyl]carbamate
  参考文献：
  名称：

  [EN] CYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME
  [FR] COMPOSÉS CYCLIQUES ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION

  摘要：

  本发明提供了用于抑制微生物生长的化合物或其药学上可接受的盐；用于治疗患有微生物感染、口腔炎、眼科感染、耳科感染、癌症或结核分枝杆菌感染的哺乳动物；用于抑制结核分枝杆菌物种的生长；用于调节哺乳动物的免疫反应；或用于拮抗非分级肝素、低分子肝素或肝素/低分子肝素衍生物。

  公开号：

  WO2013090185A1

文献信息

• [EN] CYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME<br/>[FR] COMPOSÉS CYCLIQUES ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION
  申请人：POLYMEDIX INC

  公开号：WO2013090185A1

  公开（公告）日：2013-06-20

  The present invention provides compounds, or pharmaceutically acceptable salts thereof, for inhibiting the growth of a microbe; treating a mammal having a microbial infection, mucositis, an ophthalmic infection, an otic infection, a cancer, or a Mycobacterium infection; inhibiting the growth of a Mycobacterium species; modulating an immune response in a mammal; or antagonizing unfractionated heparin, low molecular weight heparin, or a heparin/low molecular weight heparin derivative.

  本发明提供了用于抑制微生物生长的化合物或其药学上可接受的盐；用于治疗患有微生物感染、口腔炎、眼科感染、耳科感染、癌症或结核分枝杆菌感染的哺乳动物；用于抑制结核分枝杆菌物种的生长；用于调节哺乳动物的免疫反应；或用于拮抗非分级肝素、低分子肝素或肝素/低分子肝素衍生物。
• Polymeric Compounds And Methods Of Making And Using The Same
  申请人：Fan Xiaodong

  公开号：US20140308317A1

  公开（公告）日：2014-10-16

  The present disclosure provides compounds, or pharmaceutically acceptable salts thereof, for inhibiting the growth of a microbe; treating a mammal having a microbial infection, malaria, mucositis, an ophthalmic infection, an otic infection, a cancer, or a Mycobacterium infection; killing or inhibiting the growth of a Plasmodium species; inhibiting the growth of a Mycobacterium species; modulating an immune response in a mammal; or antagonizing unfractionated heparin, low molecular weight heparin, or a heparin/low molecular weight heparin derivative.

  本公开提供化合物或其药学上可接受的盐，用于抑制微生物的生长；治疗患有微生物感染，疟疾，口腔炎，眼部感染，耳部感染，癌症或结核分枝杆菌感染的哺乳动物；杀死或抑制疟原虫的生长；抑制结核分枝杆菌的生长；调节哺乳动物的免疫反应；或拮抗非分散肝素，低分子量肝素或肝素/低分子量肝素衍生物。
• CYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME
  申请人：Cellceutix Corporation

  公开号：US20150031738A1

  公开（公告）日：2015-01-29

  The present invention provides compounds, or pharmaceutically acceptable salts thereof, for inhibiting the growth of a microbe; treating a mammal having a microbial infection, mucositis, an ophthalmic infection, an otic infection, a cancer, or a Mycobacterium infection; inhibiting the growth of a Mycobacterium species; modulating an immune response in a mammal; or antagonizing unfractionated heparin, low molecular weight heparin, or a heparin/low molecular weight heparin derivative.

  本发明提供化合物或其药学上可接受的盐，用于抑制微生物的生长；治疗患有微生物感染、口腔炎症、眼部感染、耳部感染、癌症或分枝杆菌感染的哺乳动物；抑制分枝杆菌属的生长；调节哺乳动物的免疫反应；或拮抗非分散肝素、低分子量肝素或肝素/低分子量肝素衍生物。
• [EN] POLYCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME<br/>[FR] COMPOSÉS POLYCYCLIQUES ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION
  申请人：CELLCEUTIX CORP

  公开号：WO2014093225A3

  公开（公告）日：2014-08-07
• Expedient Synthesis of SMAMPs via Click Chemistry
  作者：Tsung-hao Fu、Yan Li、Hitesh D. Thaker、Richard W. Scott、Gregory N. Tew

  DOI：10.1021/ml400155a

  日期：2013.9.12

  A novel series of synthetic mimics of antimicrobial peptides (SMAMPs) containing triazole linkers were assembled using click chemistry. While only moderately active in buffer alone, an increase in antimicrobial activity against Staphylococcus aureus and Escherichia coli was observed when these SMAMPs were administered in the presence of mouse serum. One compound had minimum inhibitory concentrations (MICs) of 0.39 mu g/mL and 6.25 mu g/mL, respectively, and an HC50 of 693 mu g/mL. These values compared favorably to peptide-based antimicrobials. A correlation between the net positive charge and SMAMP antimicrobial activity was observed. The triazole linker, an amide surrogate, was found to provide better antimicrobial activity against both S. aureus and E. coli when compared to other analogues.